Previous 10 | Next 10 |
LONDON , March 12, 2019 /PRNewswire/ -- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including ...
COLUMBIA, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that it has entered into an agreement and plan of merger...
The stock market sell-off late last year was a reminder of how quickly a spell of bearish sentiment can start feeling like a full-blown rout. Go-go growth stocks were pegged back, fast momentum plays were pummelled and even high quality firms saw their prices tumble. Seasoned investors right...
The FDA has issued draft guidance for medical device makers on how to request nonbinding feedback on certain kinds of Form 483 deficiencies noted during on-site inspections. The objective is to enable them address the issues in a more timely and consistent fashion. Previously, companies co...
By Breakingviews Less than a year after becoming Chief Executive, Namal Nawana laments that sales of most of Smith & Nephew's (SNN) products are growing more slowly than their respective markets. A multibillion-dollar acquisition in a totally new area, like the potential takeover of sp...
Celldex Therapeutics (NASDAQ: CLDX ) -11% . More news on: Celldex Therapeutics, Inc, Eyenovia, Inc., Avaya Holdings Corp., Stocks on the move, Read more ...
Smith & Nephew PLC (SNN) Q4 2018 Results Conference Call February 07, 2019 03:30 AM ET Company Participants Namal Nawana - Chief Executive Officer Graham Baker - Chief Financial Officer Phil Cowdy - Head of Business Development and Corporate Affairs Conference Call Partici...
The following slide deck was published by Smith & Nephew plc in conjunction with their 2018 Q4 earnings Read more ...
Smith & Nephew ( SNN ) FY results : Revenues: $4,904M (+2.9%). More news on: Smith & Nephew plc, Healthcare stocks news, Earnings news and commentary Read more ...
Smith & Nephew plc (NYSE: SNN ): FY Non-GAAP EPS of $1.01; GAAP EPS of $0.76. More news on: Smith & Nephew plc, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Smith & Nephew SNATS Inc. Company Name:
SNN Stock Symbol:
NYSE Market:
Smith & Nephew SNATS Inc. Website:
Engineered for precision, confidence and efficiency in surgery - and compatible with the CORI ◊ Surgical System Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance for its new CATALYSTEM Primary Hip System fro...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company announces its Orthopaedics for All initiative – a global advisory board established to amplify diversity by building equity, breaking biases, and inspiring inclusion for individuals wishing to pursue a career in ort...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will sponsor tennis players participating in The Championships, Wimbledon 2024 to spotlight its advanced Sports Medicine portfolio alongside some of the greatest athletes in the world. Smith+Nephew endeavou...